Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Cervarix Stories

2009-09-11 14:25:00

WINSTON-SALEM, N.C., Sept. 11 /PRNewswire-USNewswire/ -- Sales of Merck's HPV vaccine, Gardasil, declined by a third this year, and three years after the FDA approved the drug an estimated three out of four women remain unvaccinated -- despite millions spent on advertising and lobbying for government mandates. A recent marketing study offers a reason. Michelle Steward, assistant professor of marketing at Wake Forest University, and several colleagues conducted an experiment with women,...

84b3ad08b84a2dac80735f899158bd141
2009-09-10 11:05:00

Cervical cancer vaccines have gotten quite a boost since a United States advisory panel recommended the approval of GlaxoSmithKline's Cervarix, which is expected to give Merck & Co's Gardasil a run for its money. According to an overwhelmingly favorable vote by the FDA's panel of vaccine experts on Wednesday, Cervarix appears safe and effective for females ranging in ages from 10 to 25. If the FDA follow the group's recommendations, Glaxo would engage in an intense competition against...

2009-09-10 07:46:00

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Cancer Therapies Market http://www.reportlinker.com/p0109886/World-Cancer-Therapies-Market.html This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts for the global market is provided for the period of 2006...

2009-09-09 14:53:00

PHILADELPHIA, Sept. 9 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively). CERVARIX was shown to be highly effective and well tolerated in girls and young women for the prevention of cervical...

6e8087ca2fa74af25c67a2e9cdf725961
2009-08-19 12:38:06

Researchers have found that the popular and highly advertised cervical cancer vaccine Gardasil has a low rate of side effects, but 32 deaths and questionable promotion strategies by its maker Merck & Co. has raised some concern.  Two separate studies were performed and submitted to the federal government's Vaccine Adverse Event Reporting System on girls and young women who were vaccinated with Gardasil from June 2006 through December 2008. The study found that the vaccine was known...

27fdacf7cef9734d090fa2c825da2d551
2009-07-09 11:40:00

The World Health Organization (WHO) has now approved a new cervical cancer vaccine from pharmaceutical company GlaxoSmithKline (GSK), which means that U.N. agencies and partners can now officially buy millions of doses of the vaccine for poor countries worldwide. GSK stated Thursday that the approval would help expedite the accessibility of Cervarix globally. Gardasil, the rival vaccine made by pharmaceutical company Merck & Co., was the first cervical cancer vaccine to be approved by...

2009-07-07 07:00:00

LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet. The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix(R) is highly effective at protecting against the two most common cervical cancer-causing human papillomavirus (HPV) types, 16 and 18. The study also showed that the vaccine provides cross-protection against HPV types 31, 33 and 45, the three most common cancer-causing virus types...

2009-07-01 16:12:07

Even under favorable assumptions, including lifelong protection against 70% of all cervical cancers and no side effects, vaccination against the human papillomavirus (HPV) is not cost-effective in the Netherlands, according to a study published online July 1 in the Journal of the National Cancer Institute.Researchers conducted the study because the cost effectiveness of HPV vaccination may be limited by the low number of cervical cancer cases and deaths in the region associated with the...

2009-06-08 08:01:31

 The HPV vaccine isn't just for teens. New research shows women ages 24 to 45 not already infected with the common sexually transmitted disease can receive protection against the virus following vaccination.Adolescent girls and young women have been the targets for HPV vaccination efforts. However, a rising age at first marriage, divorce and changing sexual habits has resulted in an increase in rates of HPV infection among women over the age of 24. Results of a new study show it's not...

2009-06-02 11:33:55

 Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.Mary Gerend, assistant professor of medical humanities and social sciences at the FSU College of Medicine, and Jessica Barley, a 2008 Florida State psychology graduate who based her honors...